We are excited to ring the Nasdaq opening bell in New York City today to celebrate our 25-year milestone. As a dual-listed company, earlier this year, we rang the Nasdaq bell in Copenhagen to mark this milestone. These moments symbolize our growth and evolution into a biotech innovation powerhouse. Here’s to continuing to work toward our vision that by 2030, our knock-your-socks-off KYSO antibody medicines® are transforming the lives of people with cancer and other serious diseases. Learn more: http://gmab.ly/hM9P50TeLVO. #Innovation #Biotech #Genmab25
Om os
We are an international biotech company committed to our goal of improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, our passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative, and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, and effector function enhanced antibodies. By 2030, our vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines. We are united by our core values: a passion for innovation, determination, integrity, and working as one team and respecting each other. When you work at Genmab you'll be part of a warm, fun, dynamic community seeking out and embracing the opportunity to build new and bold futures within a rapidly growing biotechnology company. Genmab is a place where you can be authentically you; you are empowered to innovate, build solutions and execute; you feel cared for and supported. In its totality, this makes working at Genmab an extra[not]ordinaryTM experience. Established in 1999, we are headquartered in Copenhagen, Denmark with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com. Disclaimer: http://bit.ly/GENDisclaimer
- Websted
-
http://www.genmab.com
Eksternt link til Genmab
- Branche
- Forskning inden for bioteknologi
- Virksomhedsstørrelse
- 1.001 – 5.000 medarbejdere
- Hovedkvarter
- Copenhagen V
- Type
- Aktieselskab
Beliggenheder
Medarbejdere hos Genmab
-
Hinrich Göhlmann
Scientific Director specializing in 𝐇𝐢𝐠𝐡-𝐃𝐢𝐦𝐞𝐧𝐬𝐢𝐨𝐧𝐚𝐥 𝐁𝐢𝐨𝐥𝐨𝐠𝐲 | Bridging Science, Data, and Technology
-
Amy D.
Director, Digital Products, Experience Management @ Genmab | Digital Transformation | ex-Amex | ex-Regeneron
-
Javier Pintado
Vice President, Global Marketing at Genmab
-
Caroline Eilering
Opdateringer
-
Genmab will attend the 12th Annual Meeting of the Society of Hematologic Oncology – covering the latest advancements and innovation in the hematology space. Connect with our colleagues and visit our booth #176 to learn more about our next-gen antibody technologies and investigational therapies. http://gmab.ly/7nPT50TeuUQ. #SOHO2024 #hematology
-
-
News Update: The European Commission has granted marketing authorization of our medicine for #BloodCancer patients with relapsed/refractory follicular #lymphoma. Learn more: http://gmab.ly/s49B50T1aHE AbbVie
-
Welcome to Genmab’s August Edition of Knock-Your-Socks-Off-News, a monthly newsletter covering our current happenings across the globe. Follow along with us on our journey for more updates as we advance innovation and continue to work towards our goal of transforming the lives of patients through antibody medicines. #culture #news #healthcare
-
At Genmab, our colleagues are passionate about making an impact on patients’ lives. With the opportunity to build new and bold futures, our colleagues embody the spirit of extra[not]ordinary®. This is our unique word, meaning we go way beyond what is usual—to be remarkable, proudly unique, and authentic. Hear from Melissa Rizzo, Manager, Field Operations on her experience working at Genmab. To #JoinGenmab, visit: http://gmab.ly/QCBu50SWQy2. #ExtraNotOrdinary
-
As we continue our journey to become a biotech innovation powerhouse, this week marks one year since Genmab opened its new headquarters. This new space in Valby, Copenhagen was designed to support our culture of innovation and collaboration. Learn more about opportunities to be a part of our team: http://gmab.ly/2MzC50SW2YG. #Biotech #Innovation
-
Putting #PatientsFirst means prioritizing patients’ needs in every aspect of our work. Hear from Keshia Carpenter, Clinical Trial Manager, as she shares how her experience as a cancer patient shapes her daily work at Genmab. Learn more about patient engagement at Genmab: http://gmab.ly/hxwV50SW32c. #InspiredByPatients
-
#InvestorUpdate: Genmab has published its Interim Report for the first half of 2024. Executive Vice President and Chief Financial Officer Anthony Pagano shares how we’re strengthening our mid-to-late pipeline of innovative antibody products to propel towards our vision of transforming the lives of people with cancer and other serious diseases. To read the report, visit: http://gmab.ly/elgM50SU4Jk. #Biotech #Innovation
-
-
#InvestorUpdate: Join us for our 2024 Interim Report for the first half of the year. To register for the event, visit: http://gmab.ly/cJU450SL2tV. #Biotech #Innovation
-
-
At Genmab, our purpose of improving the lives of patients through innovative and differentiated antibody therapeutics brings us together. We believe in creating a culture where colleagues belong to something bigger than themselves. If you are interested in learning more about becoming a part of our team, check out our new careers page at the link below, where we share colleagues' stories, extra[not]ordinary® testimonials and open positions. http://gmab.ly/a9y950SLgsY
Tilsvarende sider
Finansiering
Seneste runde
Post IPO-egenkapital134.000.000,00 US$